Last reviewed · How we verify
NCT04285398: PHENOROD2
Prospective Natural History Study of Retinitis Pigmentosa
NA trial testing Ophthalmic examinations in Retinitis Pigmentosa in 82 participants. Participants enrolled and being followed up; not accepting new ones.
30 June 2026
Quick facts
| Lead sponsor | SparingVision |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 82 |
| Start date | 12 February 2020 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 2 locations across France, United States |
Drugs / interventions tested
- Ophthalmic examinations
- Mobility Test
Conditions studied
- Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →
Sponsor
SparingVision — full company profile →
Who can join
18 and older, any sex, with Retinitis Pigmentosa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6a or PDE6b gene mutations.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Moving Towards PDE6A Gene Supplementation Therapy.
Bujakowska KM, Comander J. · · 2020 · cited 1× · PMID 33057571 · DOI 10.1001/jamaophthalmol.2020.4216
Verify or expand the search:
- PubMed search for NCT04285398
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ophthalmic examinations
Trials testing the same drug.
- NCT04219228 — Zhaoqing Myopia Study · unknown
Other recruiting trials for Retinitis Pigmentosa
Currently open trials in the same condition.
- NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
- NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting
Other SparingVision trials
Trials by the same sponsor.
- NCT03975543 — Retrospective Natural History Study of Retinitis Pigmentosa · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04285398 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SparingVision
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04285398.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing